Recent real-world data from the Turkish Oncology Group further support the effectiveness of CDK4/6 inhibitors in male patients with HR-positive/HER2-negative breast cancer [20], highlighting the importance of expanding access to modern targeted therapies in this population. The gene discussed is ERBB2; the disease is breast carcinoma.